ORIGINAL ARTICLE

Changes in Ki67 expression and clinical response to neoadjuvant chemotherapy in locally advanced breast cancer (LABC)

Desak Gede Agung Pramesti Devi , Heru Purwanto, Willy Sandhika

Desak Gede Agung Pramesti Devi
Department of Surgery, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, Indonesia. Email: desakpramesti90@gmail.com

Heru Purwanto
Oncology Surgery Division, Department of Surgery, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, Indonesia

Willy Sandhika
Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, Indonesia
Online First: November 12, 2021 | Cite this Article
Devi, D., Purwanto, H., Sandhika, W. 2021. Changes in Ki67 expression and clinical response to neoadjuvant chemotherapy in locally advanced breast cancer (LABC). Bali Medical Journal 10(3): 925-931. DOI:10.15562/bmj.v10i3.2700


Background: Locally Advanced Breast Cancer (LABC) is still the most common stage found in breast cancer patients in Indonesia. Neoadjuvant Chemotherapy (NAC) is the initial therapy and the main pillar of LABC treatment. NAC could provide less extensive surgery and improve patient’s overall survival to those who achieve a complete pathological response. Ki67 expression is a tumor biomarker representing tumor cell proliferation and has been extensively investigated as a promising predictive and prognostic factor in breast cancer. This study aims to examine the association between Ki67 expression with clinical response of NAC.

Methods: The study was designed as a case-control study in breast cancer patients who received standard anthracycline-based NAC. Clinical and immunohistochemical characteristics before and after NAC were obtained retrospectively. Changes in Ki67 and NAC responses were analyzed. Data were analyzed using SPSS version 23 for Windows

Results: A total of 66 subjects were analyzed. About 33 subjects were in good clinical response and 33 subjects were in poor clinical response. Chi-square analysis showed that no significant differences were found in the pre-treatment Ki67 expression between good and poor clinical response group, whereas a low post-treatment Ki67 expression (Ki67 <20%) was correlated with a good clinical response to NAC (p=0.027). Further analysis also showed that a decrease of Ki67 expression greater than 12.5% after treatment was significantly correlated with good clinical response (p=0.007; OR=4.67; 95%CI=1.45-15.08). In multivariate analysis, a decrease in Ki67 was significantly correlated to response in NAC (p=0.037).

Conclusion: Decreased in Ki67 greater than 12.5% was correlated with good clinical response of Anthracycline-based NAC in LABC.

References

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172.

Sasanpour P, Sandoughdaran S, Mosavi-Jarrahi A, Malekzadeh M. Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients. Asian Pac J Cancer Prev. 2018;19(9):2423–2427.

Del Prete S, Caraglia M, Luce A, Montella L, Galizia G, Sperlongano P, et al. Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience. Oncol Lett. 2019;18(4):3873–3879.

Minerva B, Ali I, Tanggo EH, Danardono E. Neutrophil lymphocyte ratio and clinical response after neoadjuvant chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil regiment in locally advanced breast cancer. Eurasian J Biosci. 2020;14(1):2473–2478.

Mulluzi AS, Ishardyanto H, Ali I, Kahar H. Platelet To Lymphocyte Ratio Relationship With Neoadjuvant Chemotherapy Of Caf Regiment Response In Locally Advanced Breast Cancer Patients. Indian J Public Heal Res Dev. 2021;12(1):223–229.

Sjöström J, Blomqvist C. Predictive factors for response to cytotoxic treatment in advanced breast cancer: a review. Acta Oncol. 1996;35(Suppl 5):84–90.

Chen R, Ye Y, Yang C, Peng Y, Zong B, Qu F, et al. Assessment of the predictive role of pre-treatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients. Breast Cancer Res Treat. 2018;170(1):35–43.

Wu Y-T, Li X, Lu L-J, Gan L, Dai W, Shi Y-L, et al. Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki-67 in Chinese breast cancer patients: A retrospective study of 525 patients. J Biomed Res. 2017;32(3):191–197.

Chen C, Zhang Y, Huang Z, Wu J, Huang W, Zhang G. Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer. Cancer Biol Med. 2019;16(3):575–586.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.

PERABOI. Panduan Penatalaksanaan Kanker. Edisi Ke-2. Jakarta: PERABOI; 2020.

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(8):1194–1220.

Zubair Z, Masood S, Khattak S, Syed AA. Predictive Factors Involved in Determining response to Neoadjuvant Chemotherapy in High Grade Serous ovarian cancer and impact of response on 5 years disease free survival and overall survival. Pakistan J Med Heal Sci. 2020;14(3):638-643.

Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast cancer (Dove Med Press). 2019;11:151–164.

Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P. Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016. JAMA Netw open. 2020;3(8):e2013226.

Widiana IK, Irawan H. Clinical and Subtypes of Breast Cancer in Indonesia. Asian Pacific J Cancer Care. 2020;5(4):281–285.

Kim K Il, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2014;17(1):40–46.

Ding Y, Ding K, Qian H, Yu X, Zou D, Yang H, et al. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer. PLoS One. 2020;15(4):e0231895.

Li L, Han D, Wang X, Wang Q, Tian J, Yao J, et al. Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis. Future Oncol. 2017;13(11):1021–34.

Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G, et al. Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(2):307–313.

Cabrera-Galeana P, Muñoz-Montaño W, Lara-Medina F, Alvarado-Miranda A, Pérez-Sánchez V, Villarreal-Garza C, et al. Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy. Oncologist. 2018;23(6):670–678.

Wiranata S, Anjani IAW, Saputra IPGS, Sadvika IGAS, Prabawa IPY, Supadmanaba IG, et al. Pre-treatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as a Stage Determination in Breast Cancer. Open Access Maced J Med Sci. 2020;8(B):1058- 1063.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0